
Employers Pulled Back on Hiring, Adding 73,000 Jobs
The economy added 73,000 jobs last month, the Labor Department reported on Friday, lower than economists' expectations. The unemployment rate slightly rose to 4.2 percent, up from 4.1 percent the month before.
In a sign that the labor market may not have been as robust as it seemed earlier this year, job gains from the past two months were also revised down by a total of 258,000, an unusually high number.
The labor market has so far continued to hold up this year. But the slower growth in payrolls signal that cracks in the job market are deepening. Economists have warned that chaotic tariff policies, immigration restrictions and job losses in the federal government could further dampen growth.
'I think we're looking at a labor market that's not absolutely falling off a cliff, but it's getting materially weaker,' said Oliver Allen, a senior U.S. economist at Pantheon Macroeconomics.
Employers added fewer jobs in July than expected, reflecting a labor market that has been moderately cooling this year as high interest rates have weighed on businesses. Last year, the economy added an average of about 168,000 jobs each month.
Economists expect President Trump's policies to more substantially hit the labor market in the coming months. Higher tariffs on dozens of countries are set to go into effect on Aug. 7. The Trump administration has reached deals with some trading partners, but officials are still finalizing the details and hashing out agreements with other countries. Lower immigration and efforts to ramp up deportations could also strain labor supply for industries that depend on foreign-born workers.
Economists say the steady pace of job gains reflect the uncertainty that businesses have faced as on-and-off again tariff policies have made it difficult to move forward with expansion plans.
'It's hard to pull the trigger on hiring when you're uncertain about where tariffs are going to land,' said Diane Swonk, the chief economist at KPMG. 'It's the uncertainty that causes the paralysis.'
The jobs report comes two days after the Federal Reserve held interest rates steady. The central bank has taken a wait-and-see approach and shown little urgency to lower rates, in part because of the labor market's durability. Two members of the Board of Governors, however, dissented.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 minutes ago
- Yahoo
Raymond James Lowers Relay Therapeutics (RLAY) PT to $19 Following Q2 Results, Strategic Cost Cuts
Relay Therapeutics Inc. (NASDAQ:RLAY) is one of the most promising penny stocks under $5. On August 8, Raymond James lowered the firm's price target on Relay Therapeutics to $19 from $29, while keeping a Strong Buy rating on the shares. This sentiment followed Relay Therapeutics' Q2 2025 results, where OpEx was down 16% sequentially following strategic cost-cutting initiatives. Relay Therapeutics reported a net loss of $70.4 million, or $0.41 per share, in Q2 2025, which was an improvement compared to the net loss of $92.2 million, or $0.69 per share, in Q2 2024. Revenue for the quarter was $0.7 million, which was an increase from zero revenue in the same period last year. A chemist arranging containers of compounds, ready for the commercialization process. This quarter also featured the initiation of the Phase 3 ReDiscover-2 trial for RLY-2608 in Q2 2025. At the 2025 American Society for Clinical Oncology/ASCO Annual Meeting, updated interim data from the Phase 1b study for RLY-2608 were presented. In addition to oncology, Relay Therapeutics is continuing to execute its ongoing Phase 1 clinical trial for vascular malformations. Relay Therapeutics Inc. (NASDAQ:RLAY) is a clinical-stage precision medicines company that transforms the drug discovery process with a focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. While we acknowledge the potential of RLAY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 minutes ago
- Yahoo
Canaccord Lowers Clover Health (CLOV) PT to $4.10 Despite Strong Q2 Growth
Clover Health Investments Corp. (NASDAQ:CLOV) is one of the most promising penny stocks under $5. On August 7, Canaccord lowered the firm's price target on Clover Health to $4.10 from $4.50, while keeping a Buy rating on the shares. The firm said the company reported solid Q2 2025 results, but the insurance benefit expense ratio came in higher than expected, which was of some concern. In Q2, the company's Medicare Advantage membership grew by over 30% year-over-year, and the insurance revenue increased by 34% to $470 million. Clover Health Investments' technology-first care model, which includes the Clover Assistant platform, showed a 15% reduction in hospitalizations and an 18% reduction in readmissions for patients with chronic obstructive pulmonary disease/COPD. An older Medicare-eligible consumer smiling happily while receiving healthcare services at a clinic. The company is now well-positioned for future growth with a 4-star payment year in 2026, which is expected to provide a financial tailwind. Clover Health is also expanding its technology platform to other risk-bearing entities, potentially opening up additional revenue streams. Clover Health Investments Corp. (NASDAQ:CLOV) is a company that provides medicare advantage plans in the US. It operates Clover Assistant, which is a software platform to execute strategy by enabling physicians to detect, identify, and manage chronic diseases earlier than they otherwise could. While we acknowledge the potential of CLOV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 minutes ago
- Yahoo
RBC Capital Cuts Algoma Steel (ASTL) PT to C$8 Following Q2 Net Loss
Algoma Steel Group Inc. (NASDAQ:ASTL) is one of the most promising penny stocks under $5. On July 31, RBC Capital lowered the firm's price target on Algoma Steel to C$8 from C$10, while maintaining a Sector Perform rating on the shares. Prior to this decision, the company released its Q2 2025 earnings. Algoma Steel Group reported a net loss of $110.6 million, which was a sharp contrast to the net income of $6.1 million in the prior year's quarter. Adjusted EBITDA was a loss of $32.4 million, which reflected a negative margin of 5.5%. This was driven by a 10.5% year-over-year decline in steel revenue to $534 million, as well as lower steel shipments of 472,000 net tons, down 6.2% from the previous year. A factory worker operating a machine that processes steel products. The average net sales realization was $1,132 per ton, a decrease from $1,187 per ton in the prior year period, while the average cost per ton of steel products sold increased by 7% year-over-year to $1,144. A major factor contributing to the financial downturn was $64 million in direct tariff costs on outbound steel shipments to the US, which is a market now effectively closed to Canadian steel producers due to prohibitive tariffs. The company also reported ending the quarter with inventories valued at $736 million, a decrease from $800 million in the prior year quarter. Algoma Steel Group Inc. (NASDAQ:ASTL) produces and sells steel products in Canada, the US, and internationally. While we acknowledge the potential of ASTL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey.